(Adnkronos) – “We have already had more than 1,500 deaths since the beginning of the year. For prevention in immunocompromised patients we have monoclonal antibodies.” Massimo Andreoni, professor emeritus of Infectious Diseases at the Tor Vergata University of Rome, told Adnkronos Salute. on the sidelines of the final National Event which took place in the capital, “The management of COVID-19 prophylaxis as a paradigm of a new organizational model” of the Prevention Management LAboratory (PMLAb) project, conceived by Dephaforum with the support of AstraZeneca Italia, during which presented the guidelines relating to the ideal organizational model for COVID-19 PrEP and the care and management of the immunocompromised patient.
#Covid #Andreoni #Tor #Vergata #disease #endemic #phase #guard
Health, La Torre (Sip Puglia): “It is important to understand the spread of RSV to combat it”
"It is very important to understand the spread of the respiratory syncytial virus (RSV) to combat it, considering that it...